Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izokibep in Active Psoriatic Arthritis
NCT05623345Phase 3Terminated
- Sponsor
- Acelyrin
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of izokibep in psoriatic arthritis (PsA), sponsored by Acelyrin. Started Nov 2022; status: terminated.
02
Drugs
izokibep
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05623345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623345.